New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease
Go back to New Data from IONIS-HTT Rx Phase 1/2 Study Demonstrates Correlation Between Reduction of Disease-causing Protein and Improvement in Clinical Measures of Huntington's Disease| (NASDAQ: AKCA) | Delayed: 18.17 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $18.17 | 52 Week High | $ | |||
| Open | $22.77 | 52 Week Low | $ | |||
| Day High | $18.17 | P/E | N/A | |||
| Day Low | $18.17 | EPS | $ | |||
| Volume | 2,023 | |||||
| (NASDAQ: IONS) | Delayed: 44.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $44.50 | 52 Week High | $62.68 | |||
| Open | $44.50 | 52 Week Low | $19.59 | |||
| Day High | $44.50 | P/E | N/A | |||
| Day Low | $44.50 | EPS | $0.00 | |||
| Volume | 264 | |||||
